Standardized protocol in preventing postoperative infectious complications after transrectal ultrasound-guided prostate biopsy: A retrospective study of 246 patients  by Chen, Pao-Hwa et al.
ble at ScienceDirect
Urological Science 27 (2016) 140e143Contents lists availaUrological Science
journal homepage: www.urol -sc i .comOriginal articleStandardized protocol in preventing postoperative infectious
complications after transrectal ultrasound-guided prostate biopsy:
A retrospective study of 246 patients
Pao-Hwa Chen*, Chin-Pao Chang, Bai-Fu Wang, Jesen Lin, Heng-Chieh Chiang,
Meng-Yi Yan, Sheng-Hsien Huang, Chun-Chi Chen, Hung-Jen Shih, Jian-Xiang Zhang
Division of Urology, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwana r t i c l e i n f o
Article history:
Received 15 April 2015
Received in revised form
24 June 2015
Accepted 28 June 2015
Available online 11 August 2015
Keywords:
biopsy
complication
infection
prostate
trans-rectal* Corresponding author. Department of Surgery, D
Christian Hospital, 135, Nanxiao Street, Changhua
Taiwan.
E-mail address: 149690@cch.org.tw (P.-H. Chen).
http://dx.doi.org/10.1016/j.urols.2015.06.292
1879-5226/Copyright © 2015, Taiwan Urological Ass
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Objective: This study was carried out to compare infectious complications between patients with and
without a set protocol for prostate biopsy.
Materials and methods: Patients whom underwent prostate biopsy at our hospital from 2001 to 2012
were ﬁrst identiﬁed. Two different groups of patients were then selected from 2 different years. The cut-
off year in which we started to implement a standardized protocol for prostate biopsy was 2007. Data
from the patient group without a set protocol were collected from January 2001 to December 2001. Data
from the patient group with a set protocol were collected from January 2012 to December 2012.
Results: A total of 246 patients were selected from 2 different years. Ninety-two patients were collected
from January to December 2001 (without set protocol). One hundred and ﬁfty-four patients were
collected from January to December 2012 (with set protocol). In the ﬁrst group, the infectious compli-
cation rate was 10.75% (10/92), whereas in the second group, the infection rate was 1.3% (2/154). All
minor complications (such as hematuria, hematospermia, dysuria, etc.) were self-resolving within 1
month. Most infectious complications were managed during outpatient department (OPD) hours with
oral antibiotics. Only one patient required hospitalization (from 2001). None of the positive culture re-
sults revealed any resistant strain species.
Conclusion: The minor complications were similar in both groups and were all self-resolving. Infectious
complications were more prevalent in the group without a set protocol. Adequate perioperative prep-
aration and postoperative antibiotic regimens appear to be helpful in the prevention of infectious
complications.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Complications of transrectal ultrasound (TRUS)-guided prostate
biopsy varies from self-resolving hematuria to life threatening
septic shock. As reported in English literature, the rate of infectious
complications ranges from 3% to 11% and the estimated severe
septic rate is <1%.1e4 Several studies have been conducted on
perioperative preparation and prophylactic antibiotics in order to
minimize post procedural infection.5e8 As prostate cancerivision of Urology, Changhua
City, Changhua County 500,
ociation. Published by Elsevier Tascreening becomes more prevalent in developing and developed
countries, the number of clinically insigniﬁcant prostate cancer
cases has been on the rise.9,10 Because most prostate cancer is
indolent and slow growing, we need to minimize the rate of life-
threatening complications for patients with this insigniﬁcant dis-
ease. Guidelines such as the American Urological Association (AUA)
and the European Association of Urology and numerous controlled
trials have shown a high level of evidence favoring the use of
prophylactic antibiotics after prostate biopsy.11e15 Owing to the
increase in the use of quinolone based antibiotics, the rate of severe
infection due to resistant strain bacteria has been on the rise.16e20
Several studies have addressed these problems with preoperative
anal swab culture guided antibiotic prophylaxis and perioperative
povidone-iodine anal preparations or formalin disinfection of bi-
opsy needles.5,7,13,15 Most of these studies have been done iniwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Figure 1. Perianal and rectal cleansing with beta-iodine.
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studies focusing on Asian countries and the Asian population. In
this study, we retrospectively review Taiwanese patients in central
Taiwan from 2 different years, one group was selected before, and
the other after, 2007.
2. Materials and methods
2.1. Patients
After obtaining Changhua Christian Hospital institutional review
board (IRB) approval (IRB number: 141114), we retrospectively
identiﬁed all the patients using the surgical code T79401C at our
hospital. Patients were then selected from 2 different years, Group 1
from2001 andGroup 2 from2012. The cut-off pointwas determined
to be in 2007 due to the fact that we started our standardized pre-
operative (gentamicin sulfate 80 mg intramuscular), perioperative
(beta-iodine rectal swap), and postoperative (levoﬂoxacin 500 mg
daily for 3 days) protocol in 2007. Prior to 2007, every attending
doctor had their own postbiopsy antibiotic regimen ranging from
sulfamethoxazole trimethoprim, cefazolin, and pipemidic acid, to
ﬂuoroquinolone. We were interested to determine if the standard-
ized protocol had helped with the control of infectious complica-
tions. All medical records were reviewed and all postoperative
complications within 14 days were recorded and analyzed.
2.2. Perioperative preparation and postoperative medications
Biopsieswere performed in the operation roomeither under local
or general anesthesia. Preoperatively, the patient was given a single
intramuscular injection of 80 mg of gentamicin sulfate (Ensafe In-
dustrial Co. Ltd. Hsin Ying City, Tainan City) 30 minutes before the
procedure. The patient was then positioned in a lateral decubitusFigure 2. Before draping the patient, the rectum is cleansed with a combination of betposition and povidone-iodinewas used for perianal disinfection and
inside the rectum (Figure 1). The patient was then draped and a
mixture of povidone-iodine with 2% xylocaine jelly (AstraZeneca
Global) was used to cleanse the rectum and provide some local
anesthesia (Figure 2). A 3-day prescription after the procedure
included: a magnesium oxide tablet 500 mg three times daily, acet-
aminophen500mg three times daily, levoﬂoxacin 500mgoncedaily,
and tranexamic acid 500 mg three times daily (optional). Patients
were then educated about common postoperative complications
(hematuria,urine retention, infection, etc.) beforedischargeandwere
told to promptly seek medical attention should complications occur.
Complications were separated into minor and major complica-
tions. Common self-resolving complications such as hematuria,
acute urine retention, dysuria, and anal pain were grouped into
“minor complications”. Any infectious complications or any com-
plications requiring hospitalization were classiﬁed as “major com-
plications”. Infectious complications are deﬁned as body
temperature >38.0C with accompanied urinary tract infection
symptoms such as chillness, frequency, urgency, and dysuria. Sepsis
was deﬁned as the presence of infection together with systemic
manifestations of infection (Table 1).21
2.3. Patient evaluation
Medical records were reviewed and any infectious complica-
tions within 14 days of the procedurewere considered to be related
to the prostate biopsy. The ClavieneDindo classiﬁcation systemwas
used to grade postoperative complications.
2.4. Statistical analysis
Patient demographics were expressed in mean values with
standard deviation and range for each variable. Fisher's exact test
was used to compare the complication between the two data sets.
Variables with p < 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Patient characteristics and perioperative data
Two-hundred and forty six patients were identiﬁed from the
following 2 years: 92 patients in 2001 and 154 patients in 2012.
More than 1500 patients underwent prostate biopsy at our hospital
in the 10-year span. Local anesthesia was used unless the patient
preferred general anesthesia (Table 2). The abnormally high value
for average prostate-speciﬁc antigen (PSA) was due to several pa-
tientswhose PSAswere in the 1000th range. The average patient age
(75 years and 71 years), BMI (24 and 26), and prostate volume (36
and 39 cm3) was similar in both year groups with a slightly highera-iodine and xylocaine jelly. The patient is then fully draped before the procedure.
Table 1
Diagnostic criteria for sepsis.
Infection, documented or suspected, with some of the following:
General parameters
Fever (core temperature >38.3C)
Hypothermia (core temperature <36C
Heart rate >90 bpm or >2 SD above the normal value for age
Tachypnea >30 bpm
Altered mental status
Signiﬁcant edema or positive ﬂuid balance (>20 mL/kg over 24 h)
Hyperglycemia (plasma glucose >110 mg/dL or 7.7 mM/L) in the absence of
diabetes
Inﬂammatory parameters
Leukocytosis (white blood cell count >12,000/mL)
Leukopenia (white blood cell count <4000/mL)
Normal white blood cell count with >10% immature forms
Plasma C reactive protein >2 SD above the normal value
Plasma procalcitonin >2 SD above the normal value
Hemodynamic parameters
Arterial hypotensionb (systolic blood pressure <90 mmHg, mean arterial
pressure <70 mmHg, or a systolic blood pressure decrease >40 mmHg in
adults or <2 SD below normal for age)
Mixed venous oxygen saturation >70%
Cardiac index >3.5 L/min/m2
Organ dysfunction parameters
Arterial hypoxemia (PaO2/FIO2 <300)
Acute oliguria (urine output <0.5 mL/kg/h or 45 mM/L for at least 2 h)
Creatinine increase#0.5 mg/dL
Coagulation abnormalities (international normalized ratio >1.5 or activated
partial
Thromboplastin time >60 s)
Ileus (absent bowel sounds)
Thrombocytopenia (platelet count <100,000/mL)
Hyperbilirubinemia (plasma total bilirubin >4 mg/dL or 70 mmol/L)
Tissue perfusion parameters
Hyperlactatemia (>3 mmol/L)
Decreased capillary reﬁll or mottling
bpm ¼ beats/min; SD ¼ standard deviation.
Table 3
Postbiopsy major and minor complications.
2001 Rate (%) 2012 Rate (%) p
Minor complications
(Clavien-Dindo Grade I)
17 18.5 21 13.6 0.36
Hematuria 10 10.9 7 4.5 0.07
Acute urine retention 3 3.3 5 3.2 1
Dysuria 2 2.2 4 2.6 1
Anal pain 1 1.1 1 0.6 1
Others 1 1.1 4 2.6 0.65
Major complications
(Clavien-Dindo Grade II)
Infection 10 10.9 2 1.3 0.001
Table 4
Infectious complications.
2001 Rate (%) 2012 Rate (%) p
Total 10 10.9 2 1.3 0.001
Ward admission 1 1.1 0 0.0 0.37
ER observation 7 7.6 1 0.6 0.004
OPD treatment 2 2.2 1 0.6 0.55
Positive blood culture 4 4.3 0 0.0 0.02
Positive urine culture 2 2.2 1 0.6 0.55
ER ¼ emergency room; OPD ¼ outpatient department.
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from a six-core biopsy to a 12-core biopsy which could explain the
higher detection rate. Our infection rate dropped from 10.9% (10/92
patients) to 1.3% (2/154 patients), which was statistically signiﬁcant
(p ¼ 0.001). Most infections were treated with oral antibiotics, only
onepatient requiredhospitalization (ClavieneDindoGrade 1 and 2).
The positive urine and blood cultures were Escherichia coli pre-
dominant and did not reveal any quinolone resistant strains.
3.2. Complications
All postoperative complications were either self-resolving or
easily managed with an adequate antibiotics regimenTable 2
Patient demographics.
Basic data 2001 Ran
Patient no. 92
Age (y) 74.6 ± 11 46e
Weight (kg) 62.8 ± 8 40e
Height (cm) 160.9 ± 6 147
BMI 24.2 ± 3 16e
Form of anesthesia
Local 88
IVGA 4
Average PSA (ng/dL) 57.52 ± 180 0.6e
Average prostate volume (cm3) 36.48 ± 16 9~8
Average transitional zone volume (cm3) 17.24 ± 12 4~5
Average number of biopsy cores 6.45 ± 1 2~1
Benign 66
Malignant 26 (28%)
Average Gleason score 5.86
BMI ¼ body mass index; IVGA ¼ intravenous general anesthesia; PSA ¼ prostate-speciﬁ(ClavieneDindo Grade 1 and 2). The postoperative complications
from the 2 years are shown in Table 3. Minor complications were
deﬁned as self-resolving complications which did not require
hospitalization such as hematuria, mild anal bleeding, acute urine
retention, etc. (ClavieneDindo Grade 1 and 2). Major complications
included infection or severe bleeding requiring admission or blood
transfusion (ClavieneDindo Grade 2 or higher) (see Table 4).
4. Discussion
Upon review of patients from the two time points we noticed a
considerable drop in the infection rate (from 10.9% to 1.3%) between
the two patient groups. A total of 12 patients (4.9%) had infectious
complications and only one patient (0.4%) needed hospital admis-
sion. This was comparable with other large population studies.22e25
In the population based screening study of 5802 patients by
Raaijmakers et al,23 the rate of postoperative fever and prostatis/
urosepsis were 3.5% and 0.4%, respectively. In the Surveillance,
Epidemiology and End Results (SEER)-Medicare study of 17,472
patients by Loeb et al,24 the infection rate was 6.9%. Several factors
could have contributed to the drop in infection rates seen between
the two groups in the current study. These factors may include thege 2012 Range p
154
102 70.7 ± 9 46e95 <0.05
82 65.35 ± 9 47e94 0.24
e172 164.5 ± 5 150e181 <0.05
32 24.1 ± 3 15e33 0.48
132
22
1033 132.57 ± 738 0.31e7698 0.34
8 38.96 ± 18 10e131 0.3
6 20.45 ± 14 1~86 0.87
0 12.24 ± 2 8~28 <0.05
96
58 (37%) 0.13
7.56 <0.05
c antigen.
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cleansing, and/or postoperative antibiotic regimens.
A major difference between the two groups was the imple-
mentation of postoperative antibiotics (a 3-day regimen of levo-
ﬂoxacin 500 mg once daily). Prior to 2007, each attending doctor
had their own preoperative and postoperative antibiotic regimens
ranging from sulfamethoxazole trimethoprim, cefazolin, and
pipemidic acid, to ﬂuoroquinolone. Textbooks and guidelines have
stated the recommendations for quinolone type antibiotics for
TRUS-guided biopsy and there have been studies which demon-
strated the superiority of levoﬂoxacin to other quinolones in terms
of minimum inhibitory concentration and urinary bactericidal ti-
ters.26 According to an AUA guideline, quinolone is the ﬁrst choice
of prophylactic antibiotics for prostate biopsy and sulfamethoxa-
zole trimethoprim is the second, however, the high prevalence of
sulfamethoxazole trimethoprim resistance to E. coli (56% in Taiwan)
warrants further investigation from urologists in Taiwan.27 Most
studies focus on preoperative prophylactic antibiotic regimens
rather than postoperative antibiotic regimens.6,11e13,15
In the current study, different doctors attending used different
preoperative antibiotic regimens, however, a noticeable drop in
infection (from 10% to 1%) was observed once a standardized
postoperative regimen of levoﬂoxacin was implemented. Several
articles have discussed perioperative preparation such as povidone
iodine swab, anal swab culture, and even formalin disinfectant to
minimize the infectious complications.5,7,28 We used iodine solu-
tions for anal preparation before prostate biopsy at both study time
points, therefore we cannot comment on the efﬁcacy of the iodine
anal preparation. In the prospective randomized trial by Abu Ghosh
et al,5 a 42% relative risk reduction was noted after rectal cleaning
with an iodine solution, however, this was not found to be statis-
tically signiﬁcant. Although the study did not show evidence for
anal cleaning, we continue to use this practice as “peace of mind”
for doctors and patients, because we feel this practice limits the
potential for complications in patients. Numerous articles suggest
different regimens for pre- and postoperative antibiotics.6,11e13,15 In
this retrospective study, we noticed that a standardized protocol
during all three aspects (pre-, peri-, and postoperative) of TRUS-
guided biopsy helped reduce infectious complications.
In conclusion, the complication and infection rates detected in
the current study were similar to those found in other reported
studies.1,3,4 Some limitations to the current study included the fact
that the study was carried out retrospectively, the lack of a control
group, and the different habits of attending doctors. Different
countries and environments will dictate the type of prophylactic
antibiotics being used. In the current study, we noticed a marked
decrease in infectious complications after implementing the stan-
dardized protocol. There may be other factors that inﬂuence the
drop in the rate of infection, such as better trained staff and better
anal cleansing methods. These factors are all interesting points of
research for future studies, preferably randomized controlled trials
with anal swab cultures to determine the microbial trends in
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